William Davalan

William Davalan

Auto-generated profile, based on publicly available information

William Davalan

McGill University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2025 in World Neurosurgery
Verified
Journal Article
Open access
WDWilliam Davalan
William Davalan
RKRoy Khalaf
Roy Khalaf
RDRoberto Jose Diaz
Roberto Jose Diaz
Synthetic data (SD) is artificially generated information that mimics the statistical characteristics and correlations of real-world data, enabling researchers to simulate variables that are challenging to obtain in routine practice while overcoming confidentiality barriers. This study aims to evaluate the utility, validity, and potential limitations of SD in glioblastoma (GBM) and brain metastases (BM) research. Three published neuro-oncology studies focusing on prognostic factors were selected: 2 involving GBM patients and 1 with BM patients. These studies were replicated using the MDClone platform, a healthcare data exploration tool that enables the creation of SD. Real-world data and SD were compared across patient demographic and outcome variables using summary statistics, normality testing, and t-test as required. 452 GBM patients and 1320 BM patients were generated with SD. Among GBM patients, longer median overall survival was associated with younger age (age70: 8.8 [95% CI: 7.4-10.2], P < 0.001), greater extent of resection (debulking: 16.8 months [95% CI 14.9-18.7] vs. biopsy: 10.9 months [95% CI: 9.6-12.3], P < 0.001), and higher serum albumin (sAlb) (sAlb40: 16.2 [95% CI: 13.4-19.1], P < 0.05). Among BM patients, lower systemic inflammation scores (neutrophil-lymphocyte-ratio, leukocyte-lymphocyte-ratio, platelet-lymphocyte-ratio, monocyte-lymphocyte-ratio, and C-reactive-protein/albumin-ratio) were associated with longer overall survival (P < 0.05). These results aligned with the findings reported in the literature. Integrating SD into clinical research offers potential for providing accurate predictive insights without compromising patient privacy.

12 December 2025 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Open access
PDF file
CPChristopher R. Pasarikovski
Christopher R. Pasarikovski
WDWilliam Davalan
William Davalan
JRJohn P. Rossiter
John P. Rossiter
RARyan Alkins
Ryan Alkins

15 April 2026 in World Neurosurgery
Verified
Journal Article
Open access
WDWilliam Davalan
William Davalan
RARyan Alkins
Ryan Alkins
Glioblastoma is the most common and aggressive primary malignant brain tumor in adults. While tumor biology plays a central role in disease progression, a substantial and growing body of evidence implicates structural and social determinants of health in mediating access to care and influencing clinical outcomes. This narrative review critically examines disparities in glioblastoma care across multiple axes, including socioeconomic status, race and ethnicity, geographic location, healthcare infrastructure, and institutional characteristics. Findings are synthesized from epidemiologic studies, health systems research, and qualitative investigations to elucidate the mechanisms by which inequities in diagnosis, treatment access, clinical trial participation, and end-of-life care arise and persist. Disparities are evident not only in low-resource settings and low-/middle-income countries, but also within high-income nations and universal healthcare systems, where sociodemographic variables continue to influence the likelihood of receiving guideline-concordant care. Emerging interventions, such as patient navigation programs, regionalization strategies, inclusive clinical trial frameworks, and policy-level reforms, offer actionable pathways to mitigate these inequities. Our findings underscore that disparities in glioblastoma care are largely systemically driven and modifiable, necessitating coordinated, equity-oriented strategies across the continuum of neuro-oncologic care.

13 March 2025 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Open access
PDF file
RARyan Alkins
Ryan Alkins
WDWilliam Davalan
William Davalan
AHAlec Hughes
Alec Hughes
DTDonatella Tampieri
Donatella Tampieri

3 December 2024 in ESMO Gastrointestinal Oncology
Verified
Journal Article
Open access
AMA.H. Mohammad
A.H. Mohammad
ERE. Rohr
E. Rohr
AMA. Moise
A. Moise
RAR.M. Abdulsalam
R.M. Abdulsalam
WDW. Davalan
W. Davalan
WFWilliam Foulkes
William Foulkes
Underdiagnosis of constitutional mismatch repair deficiency (CMMRD) syndrome leads to suboptimal cancer surveillance and management of CMMRD patients. Assessing pitfalls that led to the misdiagnosis of CMMRD is important to improve care trajectories, and to highlight the importance of accurate molecular and pathology-based assessment of patients presenting with CMMRD-associated features. A retrospective chart review of two patients with molecularly confirmed CMMRD ascertained through the Medical Genetics service of the McGill University Health Centre (MUHC) was conducted to study the pathway and pitfalls to diagnosis. Records were reviewed and summarized as timelines to depict important events relating to diagnosis and management of CMMRD patients. Unfamiliarity with CMMRD contributed to a diagnosis delay and initiation of CMMRD-specific surveillance. Pitfalls along the diagnostic pathway included inaccurate clinical information relayed to pathologists, unfamiliarity with CMMRD-defining features on immunohistochemistry (IHC) analyses, IHC variability and unreliability, and lack of awareness of the pivotal role for medical genetics in the diagnosis of CMMRD. Improved awareness of CMMRD in patients presenting with CMMRD-associated features can help guide IHC analysis and expedite referral to medical genetics for accurate molecular diagnosis. Consequently, timely CMMRD diagnosis improves surveillance and patient management and allows for appropriate genetic counseling for family members.

17 July 2026 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Open access
PDF file
WDWilliam Davalan
William Davalan
AGAlexandrine Gagnon
Alexandrine Gagnon
TBTristan Brunette-Clément
Tristan Brunette-Clément
CRClaudia Restrepo
Claudia Restrepo
KEKarim Estephan
Karim Estephan
PLPascal Lavergne
Pascal Lavergne
Background and objective: Direct cerebral revascularization remains a central therapeutic approach for Moyamoya disease (MMD) and Moyamoya syndrome (MMS). However, existing outcome data are largely derived from East Asian populations, with limited evidence characterizing North American cohorts. This study presents the experience of a Canadian university hospital with superficial temporal artery–middle cerebral artery (STA–MCA) bypass for MMD and MMS, focusing on perioperative management, surgical outcomes and graft durability. Methods: A retrospective case series was conducted, including nine patients with MMD/MMS who underwent STA–MCA bypass between December 2021 and March 2026 at the Hôpital du Sacré-Coeur de Montréal. Data on demographics, clinical presentation, perioperative care and follow-up outcomes were analyzed. Primary outcomes included bypass graft patency and ischemic or hemorrhagic events. Secondary outcomes included functional status assessed via the modified Rankin Scale and perioperative complications. Results: All patients ( n = 9) demonstrated sustained graft patency, with a median clinical follow-up of 16 months and a median radiological follow-up of 14 months. Eight patients (89%) experienced stable functional outcomes, while one (11%) experienced significant neurological decline due to postoperative complications. No ischemic events were observed during follow-up; however, one patient experienced a subdural hematoma in the immediate postoperative period, necessitating surgical intervention. Conclusion: Direct STA–MCA bypass is a viable revascularization strategy for MMD/MMS, achieving high graft patency and preventing recurrent ischemic events. It can be safely established in a Canadian center. However, the potential for complications, particularly in high-risk patients, highlights the critical importance of meticulous perioperative management and careful patient selection.